Iruxol Mono

Collagenase Clostridium Histolyticum, the active ingredient in Iruxol Mono, is an enzyme (collagenase) presented as a topical formulation for cutaneous use. It facilitates enzymatic debridement of necrotic tissue in chronic wounds, pressure ulcers, diabetic foot ulcers and other areas where necrotic tissue impedes healing.

GNH USA supplies Iruxol Mono as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution, with reliable logistics and customer support.

Iruxol Mono, an enzymatic debridement agent, is used to remove necrotic tissue in various chronic wound types.

- Chronic wounds: accelerates removal of necrotic tissue to promote healing. - Pressure ulcers: enzymatically debrides dead tissue, facilitating recovery. - Diabetic foot ulcers: helps clear necrotic areas, supporting wound closure. - Necrotic tissue removal: provides targeted enzymatic breakdown of extracellular matrix proteins.

Topical application of Iruxol Mono may be associated with local and systemic adverse reactions.

Common Side Effects: - Pain at application site - Redness or erythema - Swelling or edema - Itching or pruritus

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Infection of the wound - Systemic hypersensitivity with fever

When using Iruxol Mono, consider the following precautions to ensure safe and effective treatment.

- Assess wound suitability: ensure presence of necrotic tissue before use. - Avoid application on healthy skin or intact epithelium. - Monitor for signs of infection: increased pain, purulence, or fever. - Contraindicated in patients with known hypersensitivity to collagenase or protease enzymes. - Use with caution in patients receiving systemic anticoagulants or antiplatelet therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Iruxol Mono may interact with certain medications or topical agents; awareness of these interactions helps minimize adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other topical proteolytic enzymes: may cause excessive tissue breakdown. - Systemic anticoagulants (e.g., warfarin, heparin): increased risk of bleeding at the wound site. - Immunosuppressive therapy: heightened risk of wound infection.

Moderate Interactions (Monitor Closely): - Topical antibiotics applied to the same area: may reduce enzyme activity. - Dressings containing silver or iodine: potential inactivation of collagenase. - Systemic protease inhibitors: may diminish enzymatic efficacy.